AFMD Rasio cepet Affimed NV

This daily price chart for Affimed (AFMD) reflects the performance of a company developing advanced immune stimulants for oncology therapy, where the indicator stands at 0.00. The business is not subject to market cycles or seasonality, demonstrating recession resilience due to the specific nature of clinical trials. Operational stability is ensured by strict control over the transportation of biologics, which guarantees the preservation of drug properties and the safety of the therapy.

The ratio is calculated as the sum of cash and accounts receivable divided by current liabilities, excluding illiquid inventories. This metric assesses the company's ability to immediately settle debts without selling off inventory. For Affimed (AFMD) and its ROCK platform and immunotherapy partnerships, this is a critical marker of financial autonomy. Regular monitoring of the quick ratio allows investors to evaluate the cash stability of research centers during development periods.